Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorHubei Cancer Hospital

About this trial

Radical radiotherapy is critical for locally advanced non small cell lung cancer(NSCLC ). Our previous sturdy indicated that patients who received induction immunotherapy and subsequent radiotherapy suffered higher proportion of pneumonitis.Grade 2 or more pneumonitis patients have worse prognosis. It is urged to optimize the radiotherapy dose and target volume for patients treated with immunotherapy and radiotherapy. According to retrospective and prospective studies, omitting CTV radiation is feasible for patients undergoing concurrent radio-chemotherapy for locally advanced NSCLC. It is postulated that omitting CTV radiation for patients responded to induction therapy with immunotherapy and chemotherapy will have less pneumonitis without sacrificing the local control rate. Omitting CTV may also retain better immune function which will facilitate the immunotherapy.

Eligibility criteria

Qualifiers

Histologically or cytologically confirmed non-small cell lung cancer;

stage IIIA or IIIB or IIIC according to the 8th edition of the TNM cancer staging system of the American Joint Committee on Cancer (AJCC) and Union for International Cancer Control(UICC);

inoperable or refuses surgery after induction therapy with immunotherapy and chemoradiotherapy;

After ≥2 cycles of induction chemotherapy combined with immunotherapy, the efficacy was CR, PR or SD (with a decreasing trend);

Disqualifiers

tumor progress after induction with immunothearoy and chemotherapy

EGFR, ALK, or ROS1 mutation;

Previous thoracic radiotherapy;

grade 2 or more immune-related adverse events after induction immunotherapy

Trial design

Treatments tested in this trial

  • CTV omitted or delineated

Treatment groups

134 Participants
are divided into 2 treatment groups

Sponsors and collaborators